首頁 > 市場調查報告書 > 製藥

處方藥

市場調查報告書

商品編碼

1290363

全球代謝藥物市場 - 2023-2030年

Global Metabolism Drugs Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球代謝藥物市場的價值預計在2022年為160.9436億美元，到2030年為263.6952億美元，整個預測期的複合成長率為6.5%。

苯丙酮尿症是一種身體無法分解氨基酸苯丙氨酸的疾病，是遺傳性代謝紊亂的一種說明。幾個更著名的代謝疾病包括1型糖尿病、高雪氏病、楓糖漿尿症、胱氨酸病、法布里病、哈特努普病、亨特症候群、赫勒症候群、馮-吉爾克病和遺傳性血色素病。

通過治療疾病的根本原因和採用藥物來保持最佳的代謝功能，代謝紊亂的治療需要恢復代謝平衡。

市場動態

代謝性疾病的發病率不斷增加

苯丙酮尿症、瓜氨酸血症和楓糖尿症等代謝性疾病的發病率不斷增加，以及治療費用高昂，都促進了這些疾病的治療市場的成長。推動這一成長的其他因素包括發展中國家可支配收入的增加和醫療基礎設施的進步。

氨基酸補充劑的費用不斷上升

為了支持動物的發育、繁殖和其他功能，以及滿足動物對蛋白質的需求，預計動物飼料生產商對氨基酸的需求將增加。任何氨基酸的缺乏都可能促使動物發育緩慢，成熟較晚，對免疫或代謝刺激的反應較慢，體重低，並出現各種健康問題。

因此，氨基酸在動物飼料的製備中變得更加關鍵。動物飼料領域對氨基酸的需求也受到肉類消費和需求上升以及牲畜產量上升的推動。

與新陳代謝藥物相關的副作用

與治療代謝紊亂的藥物相關的負面作用的特點有：心率和血壓升高，胃腸道問題，失眠和睡眠障礙，口乾等。

例如，總部位於日本的安斯泰來製藥公司在2022年6月宣布，美國FDA對FORTIS進行了臨床擱置，目前正在進行1/2期試驗，同時對AT845試驗進行評估，該試驗是針對晚發性龐貝病成年人的研究性AAV基因替代療法。

COVID-19影響分析

治療代謝性疾病的藥物的供應和需求受到了COVID-19大流行的影響。由於COVID-19疫苗現在是研究機構和製藥公司的主要關注點，質譜儀、色譜儀和其他與代謝有關的研究工具的銷售量有些下降。因此，預計2020年影響新陳代謝的藥物市場將出現大幅下降。

俄羅斯-烏克蘭衝突分析

俄羅斯對烏克蘭的入侵影響到全世界數百萬人。藥品開發商勢必面臨整個開發過程的延誤，業務連續性的喪失，以及已經上市的藥品不符合規定的危險。

俄烏衝突影響了研發方面的投資，由於這個原因，原料的進出口停止了，同時投資者在這一時期也表現出較少的興趣，這對新陳代謝藥物市場產生了影響。

Market Overview

The Global Metabolism Drugs Market is expected to be valued at USD 16,094.36 million in 2022 and USD 26,369.52 million by 2030, with a CAGR of 6.5% throughout the forecast period.

Phenylketonuria, a disease in which the body is unable to break down the amino acid phenylalanine, is an illustration of a genetic metabolic disorder. Several more well-known metabolic diseases include type 1 diabetes, Gaucher's disease, maple syrup urine disease, cystinosis, Fabry disease, Hartnup disease, Hunter syndrome, Hurler syndrome, Von Gierke disease, and hereditary hemochromatosis.

By treating the underlying cause of the illness and employing medications to preserve optimal metabolic function, the treatment for metabolic disorders entails restoring metabolic balance.

Market Dynamics

Increasing Prevalence Of Metabolic Disorders

The increasing prevalence of metabolic disorders like phenylketonuria, citrullinemia, and maple syrup urine disease, as well as the high cost of treatments, have all contributed to the growth of the market for treatments for these disorders. Other factors driving this growth include rising disposable income in developing nations and the advancement of healthcare infrastructure.

The Rising Expense of Amino Acid Supplements

The demand for amino acids is predicted to increase among producers of animal feed in order to support animal development, reproduction, and other functions as well as to meet the animals' need for protein. Any amino acid deficit may cause animals to develop slowly, mature later, respond less quickly to immunological or metabolic stimuli, have low body weights, and have various health issues.

As a result, amino acids are becoming more crucial in the preparation of animal feed. The need for amino acids in the animal feed sector is also being driven by rising meat consumption and demand, as well as rising livestock output.

Side Effects Associated With Metabolism Drugs

Among the characteristics that have negative effects associated with drugs for metabolic disorders are increased heart rate and blood pressure, gastrointestinal issues, insomnia and sleep disturbance, dry mouth, etc.

For instance, Astellas Pharma, a pharmaceutical company based in Japan, in June 2022, announced that the USFDA put a clinical hold on FORTIS, which is currently undergoing a Phase 1/2 trial while evaluating the AT845 trial, which was an investigational AAV gene replacement therapy for adults with Late Onset Pompe Disease.

COVID-19 Impact Analysis

The supply and demand for medications that treat metabolic disorders have been affected by the COVID-19 pandemic. Since the COVID-19 vaccine is now the primary focus of research institutions and pharmaceutical corporations, sales of mass spectrometry, chromatography, and other metabolism-related research tools have somewhat decreased. The market for medications that affect metabolism is thus anticipated to see a significant drop in 2020.

Russia- Ukraine Conflcit Analysis

Russia's invasion of Ukraine affects millions of people worldwide. Drug developers are bound to face delays throughout the development process, a loss of business continuity, and the danger of non-compliance for pharmaceuticals already on the market.

The Russia-Ukraine conflict affected the investments in R&D due to which the import and exports of raw materials stopped and also investors were showing less interest during that period, which was affecting the metabolism drugs market.

Segment Analysis

The Diabetes Segment Will Dominate The Market In The Forecast Period.

The diabetes segment is estimated to hold about 35.6% of the global metabolism drugs market as plasma-free fatty acids (FFA) are more prevalent in diabetic individuals, diabetes may affect the way some medicines attach to plasma proteins, perhaps through glycosylation or protein displacement. However, albumin and 1-acid glycoprotein plasma concentrations wouldn't alter. Contrary to experimental research, the majority of medicines' metabolic clearance in people seems to be unaltered or slightly reduced in diabetes.

Geographical Analysis

North America is the Dominating Region During The Forecast Period.

Geographically, there are four regions that make up the worldwide market for metabolic disorders: North America, Europe, Asia Pacific, and the rest of the world (RoW). Due to the availability of cutting-edge technology and the greater penetration of diabetes care services throughout the region, North America is anticipated to lead the market throughout the projected period. North America is estimated to hold about 37.8% of the global metabolism drugs market.

Due to the high incidence of diabetes among the elderly population, the United States constituted a significant regional contributor. Over 25% of Americans with diabetes are 65 years of age or older, according to the American Diabetes Association. Over the projected period, Asia Pacific is anticipated to overtake North America as the region with the largest market for metabolic disorders. The region's healthcare reforms and an increase in the number of diabetics, particularly in India, are expected to drive the growth of the Asia Pacific market.

Competitive Landscape

The major global players include: Merck Sharp and Dohme Corp, Novartis AG, Amicus Therapeutics, AstraZeneca, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Sanofi, GlaxoSmithKline Plc, Horizon Therapeutics, and BioMarin Pharmaceuticals.

Why Purchase the Report?
To visualize the global metabolism drugs market segmentation based on the drug class, indication, distribution channels and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global metabolism drugs market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global metabolism drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Drug Class
3.2. Snippet by Indication
3.3. Snippet by Distribution Channels
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased prevalence of amino acid metabolism
- 4.1.2. Restraints
  - 4.1.2.1. Side effects associated with metabolism drugs
- 4.1.3. Opportunity
  - 4.1.3.1. The rising expense of amino acid supplements and Health Benefits
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Drug Class

7.1. Antidiabetic Drugs
7.2. Lipid Lowering Drugs
7.3. Anti- Obesity Drugs
7.4. Thyroid Hormone Drugs
7.5. Others

8. By Indications

8.1. Diabetes
8.2. Hyperlipidemia
8.3. Obesity
8.4. Hypothyroidism

9. By Distribution Channel

9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country